Clifford A. Brass

Statistics

Publications

Citations

12.4K

H-Index

Active since

1981

Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)(Current)

Cornell University

Cedars-Sinai Medical Center

Johns Hopkins University

Sorbonne Université

Clifford A. Brass is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in viral hepatitis, antiviral therapy, and pharmacotherapy.

Publications per year

1981–2025

Publications

Boceprevir for Untreated Chronic HCV Genotype 1 Infection

Fred Poordad, Jonathan McCone, Bruce R. Bacon et al. · New England Journal of Medicine · 2011 · 2.5K citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +17

Boceprevir for Previously Treated Chronic HCV Genotype 1 Infection

Bruce R. Bacon, Stuart C. Gordon, Eric Lawitz et al. · New England Journal of Medicine · 2011 · 1.6K citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +17

Peginterferon Alfa-2b or Alfa-2a with Ribavirin for Treatment of Hepatitis C Infection

John G. McHutchison, Eric Lawitz, Mitchell L. Shiffman et al. · New England Journal of Medicine · 2009 · 1.2K citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +14

Interleukin-28B Polymorphism Improves Viral Kinetics and Is the Strongest Pretreatment Predictor of Sustained Virologic Response in Genotype 1 Hepatitis C Virus

Alexander Thompson, Andrew J. Muir, Mark S. Sulkowski et al. · Gastroenterology · 2010 · 723 citations · Full text

Life Sciences, Immunology, Infectious Diseases +17

Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial

Paul Y. Kwo, Eric Lawitz, Jonathan McCone et al. · The Lancet · 2010 · 704 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +17

1–5 of 89